Research Type: Policy Paper

In January 2019, ICER launched a year-long project to engage with experts, US stakeholders, and influential international agencies to develop, test, and build consensus around methodological options for determining value-based prices for potential cures. ICER will ultimately create a roadmap for value assessment of potential cures that will have a direct and significant impact on […]

The combination of rising drug costs at the health system level and increasing financial stress for individual patients has triggered intense national concern. One target has come under particular scrutiny: rebates. Drug makers in the US face no federal process whereby prices are evaluated in comparison to evidence of clinical benefit, but they must negotiate […]